Patents Examined by Brian Gangle
-
Patent number: 11931405Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).Type: GrantFiled: July 28, 2022Date of Patent: March 19, 2024Assignees: GlaxoSmithKline Biologicals S.A.Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
-
Patent number: 11925677Abstract: A method for treating chronic pancreatitis and diabetes type II in a patient in need thereof comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, a sacral nerve, or a combination thereof.Type: GrantFiled: July 11, 2022Date of Patent: March 12, 2024Assignee: Penland FoundationInventor: Roland M. Williams
-
Patent number: 11918636Abstract: An oral vaccine for immunization against ETEC-induced diarrhea, comprising inactivated Escherichia coli cells expressing an ETEC colonization factor antigen and dmLT protein adjuvant, wherein the vaccine preferably comprises less than 1013 cells per unit dose.Type: GrantFiled: July 1, 2021Date of Patent: March 5, 2024Assignee: SCANDINAVIAN BIOPHARMA HOLDING AB, C/O ETVAX ABInventors: Ann-Mari Svennerholm, Joshua Tobias, Nils Carlin, Jan Holmgren
-
Patent number: 11918610Abstract: Methods for preventing, treating or diagnosing Type 1 Diabetes (T1D) are described. Amyloid-producing bacteria within microbiota are inactivated. Amyloid-producing bacteria are inactivated in microbiota, gastrointestinal tract, bodily fluids or tissues. Type-1 Diabetes associated microbial product production or release by microbiota is prevented. Also described is inactivation of bacteria-derived T1DAMP present in microbiota, bodily fluids or tissues of a mammal. Release of bacteria-derived T1DAMP from biofilm or bacteria to gastrointestinal tract is inhibited. Entry of bacteria-derived T1DAMP to microbiota, gastrointestinal tract, bodily fluids or tissues of a mammal is inhibited.Type: GrantFiled: June 28, 2019Date of Patent: March 5, 2024Inventors: Viktor Veniaminovich Tets, Georgy Viktorovich Tets
-
Patent number: 11918635Abstract: A method and a platform for detecting an immunogenicity of a tumor neoantigen are provided. Specifically, the detection method includes the following steps: culturing human peripheral blood monocytes ex vivo for 13 days, adding an antigenic peptide fragment of human influenza virus and stimulating and activating cytokines, antigenic peptides, and immunoadjuvants during the 13 days, and finally conducting enzyme-linked immunospot (ELISPOT) chromogenic reaction and instrument-based scanning, counting, and analysis to detect the immunogenicity of tumor neoantigen. An application of the detection method and platform in biomedicine is provided. Compared with the prior art, the detection method and platform have advantages and characteristics of a short detection period, high convenience, low consumption of experimental cells, and low detection cost. Therefore, the detection method and platform can be used for ex vivo high-throughput assay for the immunogenicity of the tumor neoantigen.Type: GrantFiled: August 21, 2020Date of Patent: March 5, 2024Assignees: NeoCura Bio-Medical Technology Co., Ltd, Beijing Neocurna Biotechnology corporation, Shenzhen Neocurna Biotechnology corporationInventors: Youdong Pan, Qi Song, Ji Wan, Jun-Yuan Huang, An Xiao, Gang Liu, Ying Wen
-
Patent number: 11921119Abstract: A method of determining a management course for treating a subject showing symptoms of a disease is disclosed. The method comprises measuring the TRAIL protein level in a blood sample of the subject, wherein when the TRAIL level is above a predetermined amount, the subject is treated as a low-risk patient.Type: GrantFiled: October 22, 2020Date of Patent: March 5, 2024Assignee: MeMed Diagnostics Ltd.Inventors: Niv Steven Mastboim, Tanya Michelle Gottlieb, Kfir Oved, Eran Eden
-
Patent number: 11911419Abstract: The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating epilepsy, epileptic seizures and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.Type: GrantFiled: September 27, 2019Date of Patent: February 27, 2024Assignee: Finch Therapeutics Holdings LLCInventor: Thomas Julius Borody
-
Patent number: 11912788Abstract: Provided are peptides that are derived from probiotic bacteria that have use for preventing and/or treating non-enteric infections in a subject. The peptides derived from the probiotic bacteria also have use for reducing the virulence of non-enteric infections in a subject. Also provided are compositions of the peptides formulated as or within food products, beverages, nutritional supplements, medicaments and the like.Type: GrantFiled: March 16, 2018Date of Patent: February 27, 2024Assignee: MICROSINTESIS INC.Inventors: Monica Angela Cella, Sarah M. Curtis, Jonathon Patrick Roepke
-
Patent number: 11911418Abstract: Described is a method for the treatment or prevention of GI tract dysbiosis in a subject, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. The invention further provides a method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, malnutrition, chronic fatigue syndrome, autism, cardiovascular diseases and GI tract infections in a subject with GI tract dysbiosis, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. A non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus for use in said methods is further provided.Type: GrantFiled: April 12, 2022Date of Patent: February 27, 2024Assignees: Norges Miljo-Og Blovitenskapelige Universitet (NMBU), Sykehuset Ostfold HF, University of CopenhagenInventors: Tor Lea, Charlotte Kleiveland, Karsten Kristiansen, Benjamin Anderschou Holbech Jensen, Jacob Bak Holm, Ida Sogaard Larsen, Morten Jacobsen
-
Patent number: 11905325Abstract: Provided is a method capable of producing a protein at a high level using a cultured animal cell, comprising culturing a cell that expresses APES (Antibody Production Enhancing Sequence) and into which a DNA encoding a desired polypeptide has been introduced, thereby producing the desired polypeptide. APES contains a nucleotide sequence related to nuclear factor ?B inhibitor ? (NfkBia) and has a function of decreasing the intracellular expression of NfkBia.Type: GrantFiled: April 23, 2021Date of Patent: February 20, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hisahiro Tabuchi, Tomoya Sugiyama
-
Patent number: 11906507Abstract: A method of taking a skin sample can include placing an adhesive onto a portion of skin and lifting the adhesive from the skin. A skin sample may then be tested while still on the adhesive, for example, by inoculating the sample with a bacterium, fungus, virus, or a combination.Type: GrantFiled: March 24, 2021Date of Patent: February 20, 2024Assignee: The Procter & Gamble CompanyInventors: Karl Shiqing Wei, Feng Yue, Hechuan Yu
-
Patent number: 11906520Abstract: The invention relates to antibodies, which bind a peptide having a sequence selected from SEQ ID NO: 2, or a fragment or derivative of such an antibody having essentially the same antigen specificity. In particular, the antibodies suited to be used to detect, manage or monitor cancer in a subject, particularly cancer with interleukin-4 induced gene 1 (IL4I1) expressing cells. The invention also relates to kits or devices containing said antibodies, suitable for immunologic detection or reaction from any biological sample.Type: GrantFiled: November 22, 2019Date of Patent: February 20, 2024Assignees: Centre National De La Recherche Scientifique, Institut National De La Sante Et De La Rech. Med., Universite Paris Est Creteil Val De MarneInventors: Valérie Molinier Frenkel, Flavia Castellano
-
Patent number: 11904014Abstract: The invention relates to the use of melanin, complexed with an antigen, as a immunostimulatory composition.Type: GrantFiled: November 4, 2020Date of Patent: February 20, 2024Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITÉ Paris 13Inventors: Antoine Carpentier, Claire Banissi
-
Patent number: 11896653Abstract: A silicified cell replica includes a silicified cell or a silicified subcellular fragment. The silicified cell replica may be used to induce an immunological response, treat a bacterial infection, or treat a patient with cancer.Type: GrantFiled: September 13, 2018Date of Patent: February 13, 2024Assignee: UNM Rainforest InnovationsInventors: Rita E. Serda, C. Jeffrey Brinker, Jacob Ongudi Agola, Jimin Guo, Sarah Adams
-
Patent number: 11897927Abstract: Provided herein are recombinant fusion polypeptides comprising one or more antigenic peptides (e.g., fused to a PEST-containing peptide) from cancer-associated proteins. The antigenic peptides can comprise one or more or all of an antigenic peptide comprising a recurrent cancer mutation, an antigenic peptide comprising a heteroclitic mutation, or an antigenic peptide fused to a ubiquitin protein. For example, provided herein are recombinant fusion polypeptides comprising two or more antigenic peptides (e.g., fused to a PEST-containing peptide), wherein each antigenic peptide comprises a recurrent cancer mutation, and wherein at least two of the antigenic peptides are fragments of the same cancer-associated protein. Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains.Type: GrantFiled: November 30, 2017Date of Patent: February 13, 2024Assignee: ADVAXIS, INC.Inventors: Robert Petit, Michael F. Princiotta, Brandon Coder, David Balli
-
Patent number: 11898156Abstract: The present invention relates to vesicles derived from genus Morganella bacteria and a use thereof, the present inventors experimentally confirmed that the vesicles were significantly decreased in clinical samples derived from patients with a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer and lymphoma, a cardiovascular disease such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and stroke, diabetes mellitus, and Parkinson's disease as compared to normal persons, and the vesicles suppressed the secretion of inflammatory mediators by pathogenic vesicles and suppressed the occurrence of cancer, so that the vesicles derived from genus Morganella bacteria may be usefully used for the purpose of developing a method for diagnosing a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder canceType: GrantFiled: October 28, 2020Date of Patent: February 13, 2024Assignee: MD HEALTHCARE INC.Inventor: Yoon-Keun Kim
-
Patent number: 11896628Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.Type: GrantFiled: July 1, 2022Date of Patent: February 13, 2024Assignee: Artugen Therapeutics Ltd.Inventors: Ronald Farquhar, Christopher K. Murphy, Colin Hill, Paul Ross, Mary Rea, Michelle O'Donnell, Brian Healy, Laurent Chesnel
-
Patent number: 11891629Abstract: The invention provides propagator cells and methods for propagating phage and transduction particles.Type: GrantFiled: August 8, 2018Date of Patent: February 6, 2024Assignee: SNIPR TECHNOLOGIES LIMITEDInventor: Jasper Clube
-
Patent number: 11885817Abstract: Epileptic seizures are difficult to diagnose and are often difficult to distinguish from several conditions with similar presentations, and therefore, diagnosis of seizures is often a long, expensive, and unreliable process. This invention provides biomarkers for identifying seizures and epilepsy, assays for measuring and assessing biomarker concentration, predictive models based on biomarkers and computational systems for detecting, assessing and diagnosing phasic and tonic changes associated with seizures and epilepsy in all clinical and healthcare settings. Diagnostic and treatment methods, systems, kits, and predictive models provided herein, provide quantitative and/or qualitative assessment in order to allow patients to proceed immediately to diagnostic and/or treatment protocols, and assess therapeutic treatment effectiveness.Type: GrantFiled: May 16, 2018Date of Patent: January 30, 2024Assignee: Cognizance Biomarkers, LLCInventors: Todd Wallach, Elisa A. Waxman, John Gledhill, Richard St. Clair, Elizabeth Brand
-
Patent number: 11883440Abstract: Provided are vesicles derived from bacteria belonging to the genus Proteus and a use thereof. The inventors of the present invention experimentally confirmed that the vesicles was significantly reduced in samples of patients with cancers, allergic-respiratory diseases, cardiovascular diseases, metabolic diseases, or neuropsychiatric diseases, as compared to that of normal people, and the vesicles inhibited the secretion of inflammatory mediators due to pathogenic vesicles and also exhibited anticancer efficacy. Therefore, it is anticipated that the vesicles derived from bacteria belonging to the genus Proteus, according to the present invention, may be usefully used for the development of a method of diagnosing cancer, cardiovascular diseases, metabolic diseases, neuropsychiatric diseases, allergic-respiratory diseases, and inflammatory bowel diseases, and a composition for prevention, treatment, and/or alleviation.Type: GrantFiled: February 15, 2021Date of Patent: January 30, 2024Assignee: MD HEALTHCARE INC.Inventor: Yoon-Keun Kim